

Feasibility of Goal-Directed Fluid Therapy in Patients with Transcatheter Aortic Valve Replacement — An Ambispective Analysis

Ralf Felix Trauzeddel¹, MD; Michael Nordine², MD; Giovanni B. Fucini³, MD; Michael Sander⁴, MD; Henryk Dreger⁵, MD; Karl Stangl⁶, MD; Sascha Treskatsch¹, MD; Marit Habicher⁴, MD

¹Department of Anesthesiology and Intensive Care Medicine, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Campus Benjamin Franklin, Berlin, Germany.

²Department of Anesthesiology, Intensive Care Medicine, and Pain Therapy, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Hessen, Germany.

³Institute of Hygiene and Environmental Medicine and National Reference Center for the Surveillance of Nosocomial Infections, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

⁴Department of Anesthesiology, Operative Intensive Care Medicine, and Pain Therapy, Justus Liebig University of Giessen, Hessen, Germany.

⁵Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charité – Medical Heart Center of Charité and German Heart Institute Berlin, Campus Virchow-Klinikum, Berlin, Germany.

⁶Department of Cardiology and Angiology, Deutsches Herzzentrum der Charité – Medical Heart Center of Charité and German Heart Institute Berlin, Campus Charité Mitte, Berlin, Germany.

This study was carried out at the Department of Anesthesiology and Intensive Care Medicine, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Campus Charité Mitte, Berlin, Germany.

ABSTRACT

Introduction: Goal-directed fluid therapy (GDFT) has been shown to reduce postoperative complications. The feasibility of GDFT in transcatheter aortic valve replacement (TAVR) patients under general anesthesia has not yet been demonstrated. We examined whether GDFT could be applied in patients undergoing TAVR in general anesthesia and its impact on outcomes.

Methods: Forty consecutive TAVR patients in the prospective intervention group with GDFT were compared to 40 retrospective TAVR patients without GDFT. Inclusion criteria were age ≥ 18 years, elective TAVR in general anesthesia, no participation in another interventional study. Exclusion criteria were lack of ability to consent study participation, pregnant or nursing patients, emergency procedures, preinterventional decubitus, tissue and/or extremity ischemia, peripheral arterial occlusive disease grade IV, atrial fibrillation or other severe heart rhythm disorder, necessity of usage of intra-aortic balloon pump. Stroke volume and stroke volume variation were determined with

uncalibrated pulse contour analysis and optimized according to a predefined algorithm using 250 ml of hydroxyethyl starch.

Results: Stroke volume could be increased by applying GDFT. The intervention group received more colloids and fewer crystalloids than control group. Total volume replacement did not differ. The incidence of overall complications as well as intensive care unit and hospital length of stay were comparable between both groups. GDFT was associated with a reduced incidence of delirium. Duration of anesthesia was shorter in the intervention group. Duration of the interventional procedure did not differ.

Conclusion: GDFT in the intervention group was associated with a reduced incidence of postinterventional delirium.

Keywords: Atrial Fibrillation. Transcatheter Aortic Valve Replacement. Stroke Volume. Control Groups. Incidence. Cardiac Conduction System Disease. Fluid Therapy. Ischemia. Delirium.

Abbreviations, Acronyms & Symbols

AKIN	= Acute Kidney Injury Network	LOS	= Length of stay
AS	= Aortic stenosis	LVEF	= Left ventricular ejection fraction
AUC _{roc}	= Area under the receiver operating characteristic curve	MAC	= Monitored anesthesia care
BMI	= Body mass index	MAP	= Mean arterial pressure
CI	= Confidence interval	PACU	= Postanesthesia care unit
CO	= Cardiac output	POD	= Postoperative delirium
CVP	= Central venous pressure	PPV	= Pulse pressure variation
DO ₂	= Delivery of oxygen	RBC	= Red blood cells
EuroSCORE	= European System for Cardiac Operative Risk Evaluation	RCTs	= Randomized controlled trials

Correspondence Address:

Ralf Felix Trauzeddel

 <https://orcid.org/0000-0003-3827-8895>

Department of Anesthesiology and Intensive Care Medicine, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Campus Benjamin Franklin
Hindenburgdamm 30, Berlin, Germany
Zip Code: 12203
E-mail: ralf-felix.trauzeddel@charite.de

Article received on December 27th, 2022.

Article accepted on July 19th, 2023.

FFP	= Fresh frozen plasma	SOP	= Standard operating procedure
GDFT	= Goal-directed fluid therapy	SV	= Stroke volume
HAES	= Hydroxyethylstarch	SV_{od}	= Stroke volume measured via esophageal Doppler
HF	= Heart frequency	SV_{vig}	= Stroke volume measured via FloTrac®
IBP	= Invasive blood pressure	SVV	= Stroke volume variation
ICU	= Intensive care unit	TAVR	= Transcatheter aortic valve replacement
LBBB	= Left bundle branch block		

INTRODUCTION

Transcatheter aortic valve replacement (TAVR) has become an alternative treatment for symptomatic patients with severe aortic stenosis (AS) not eligible for surgical aortic valve replacement due to a high periprocedural risk or relevant comorbidities^[1-3]. Nevertheless, TAVR is still associated with possible periinterventional complications such as cardiac arrhythmias, renal failure, or neurological dysfunctions^[4].

The main anesthesiological objectives besides choice of the optimal anesthesia technique for the individualized patient are to maintain hemodynamic stability and sufficient tissue perfusion and oxygenation during the procedure. Optimization of preload is of particular importance to increase left ventricular stroke volume (SV) and thus delivery of oxygen (DO₂). This can potentially be achieved by applying the concept of goal-directed fluid therapy (GDFT). Several randomized controlled trials (RCTs) as well as meta-analyses have shown that GDFT is associated with fewer postoperative complications and shorter hospital stays in surgery^[5-8]. In the clinical routine, it is also shown that GDFT is feasible and associated with a better outcome^[9]. Its concept has been applied to various intensive care medicine as well as non-cardiac and cardiac surgical patients^[10-14].

However, as far as the authors are aware, there exist no data on the feasibility of GDFT based on SV optimization during TAVR. Therefore, we examined whether GDFT could be applied in patients undergoing TAVR in general anesthesia. Additionally, we examined whether GDFT in TAVR would have an impact on postoperative outcomes compared to fluid replacement based on clinical standard without GDFT.

METHODS

Study Population

Patients in the intervention group were originally consecutive participants in a two-arm pilot study in intraoperative thermal management using a noninvasive warming system in minimally invasive heart valve replacement. As GDFT was also applied in the study, data were also analyzed regarding hemodynamic optimization in TAVR. Therefore, in this ambispective substudy, patients in the prospective intervention group with GDFT were compared with a retrospective control group before the hemodynamic optimization protocol was implemented. Inclusion criteria were age \geq 18 years, elective TAVR in general anesthesia,

and no participation in another interventional study. Exclusion criteria were lack of ability to consent study participation, pregnant or nursing patients, emergency procedures, preinterventional decubitus, tissue and/or extremity ischemia, peripheral arterial occlusive disease grade IV, atrial fibrillation or other severe heart rhythm disorders which impeded usage of uncalibrated pulse contour analysis because of its insufficient validity in these disorders, and necessity of usage of intra-aortic balloon pump. All procedures performed in studies involving humans were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The study was approved by the local ethics committee at Charité – Universitätsmedizin Berlin (EA 1/142/10) and registered at ClinicalTrials.gov (NCT01176110). Informed written consent was obtained from all study patients in the intervention group. Data from patients in the retrospective control group before GDFT implementation were collected anonymously, therefore informed written consent was waived. The study was performed at the Charité – Universitätsmedizin Berlin, Campus Charité Mitte. Our study adheres to CONSORT guidelines.

Study Protocol

General anesthesia during TAVR was induced according to our local standard operating procedure (SOP) with fentanyl (1-4 $\mu\text{g}/\text{kg}^{-1}$) or remifentanyl (0.5 $\mu\text{g}/\text{kg}/\text{min}$), etomidate (0.2 mg/kg), and cis-atracurium (0.1 mg/kg), if necessary. Anesthesia was maintained with a continuous infusion of propofol (4-6 $\text{mg}/\text{kg}^{-1} \text{h}^{-1}$) and remifentanyl (0.1-0.2 $\mu\text{g}/\text{kg}^{-1} \text{min}^{-1}$). Lungs of patients were ventilated with pressure control ventilation with a tidal volume of 8-10 ml/kg^{-1} ideal body weight. End-tidal CO₂ was kept between 35 and 40 mmHg. Before induction of general anesthesia, hemodynamic monitoring was established including invasive blood pressure measurement via right or left radial artery besides electrocardiogram, pulse oximetry, temperature, central venous pressure (CVP), and body core temperature through a urine catheter. Patients were extubated immediately after TAVR and transferred to an intensive care unit (ICU) or postanesthesia care unit (PACU) for further treatment and monitoring. Haemodynamic optimization in the intervention group was performed based on SV monitored using a pulse contour method (Vigileo®, Edwards Lifesciences, Irvine, California, United States of America) and a special pressure transducer (FloTrac system®, Edwards Lifesciences). After determining individual baseline SV,

an intravenous bolus of 250 ml of a colloid fluid replacement solution (6% hydroxyethylstarch [HAES] 130/0.4, Volulyte 6%®, Fresenius Kabi GmbH, Bad Homburg, Germany) was given within five minutes and consecutively repeated until no further increase of SV \geq 10% could be achieved. The last successful fluid challenge resulting in an SV increase $<$ 10% defined the optimum SV. In case of intraoperative decrease of SV, further fluid replacement was performed. After valve implantation, the optimal SV again was defined by infusion of 250 ml colloid. Responders (Δ SV $>$ 10%) received additional volume boluses until Δ SV was $<$ 10%. Vasoactive medications were applied to maintain normotensive blood pressure values (mean arterial pressure [MAP] 65-100 mmHg, systolic blood pressure $>$ 100 mmHg and $<$ 140 mmHg). Inotropes were applied in case of insufficient increase in SV after fluid bolus according to the internal SOP of the department. Patients in the control group were monitored and treated at the discretion of the attending anesthesiologist based on internal SOP and clinical standard but without a fluid optimization strategy. The study protocol is represented in Figure 1.

Outcome Variables

As the primary endpoint for the first study was the intravesical temperature at the end of the intervention, no explicit endpoint was defined for the current GDFT study. Regarding the feasibility of SV optimization by GDFT as the primary research question of this study, it was assumed that a case number of 40 study participants would be sufficient based on previous studies^[15]. Other outcome variables were an increase of cardiac output (CO) and changes in SV variation (SVV) and complications, defined as delirium, infections (pneumoniae, urinary tract infection, wound infection), postoperative bleeding, acute kidney injury, cardiac or pulmonary complications or death of any cause as well as total length of hospital and ICU or PACU stay after TAVR, reduction in need of catecholamines or blood transfusions, reduction in postinterventional morbidity and mortality, duration of mechanically invasive ventilation, or dialysis.

Statistical Analysis

Based on the previous pilot study character, a distinct power analysis was not performed, and an explorative data analysis was performed. Statistical analysis was done using IBM SPSS Statistics for Windows, version 21.0, Armonk, NY: IBM Corp. All data were checked for normal distribution using the Kolmogorov-Smirnov test. Non-normally distributed data are expressed as median with 25th to 75th percentiles, normally distributed data are expressed as mean and standard deviation. Morphometric and demographic data of both groups were examined for comparability by Mann-Whitney U test for non-normally distributed variables and Student's *t*-test for unrelated samples for normally distributed variables. To evaluate the success of our intervention protocol, SV and SVV at different points in time of the intervention were compared using the Mann-Whitney U test. The occurrence of at least one postoperative complication was tested for independence using Fisher's exact test for nominal variables. To test for statistical difference between both groups, primary and secondary outcome variables were compared using the Mann-Whitney U test, and the Fisher's exact test was used for nominal variables.

RESULTS

Patients' Characteristics

All study participants were treated between February 2010 and March 2011 at a single institution of the Charité–Universitätsmedizin Berlin (Berlin, Germany). Eighty patients undergoing elective TAVR were included: a) intervention group (N=40), and b) control group (N=40). Basic characteristics are shown in Table 1. There were no statistically significant differences between both groups in the demographic baseline data. The preoperative risk profile of the two patient groups according to the European System for Cardiac Operative Risk Evaluation (EuroSCORE) I, EuroSCORE II, and preoperative left ventricular ejection fraction also showed no significant differences. Transfemoral access was the predominant route in both groups.

Outcome Parameters

The course of hemodynamic parameters during TAVR in the interventional group can be seen in Table 2. After induction of general anesthesia, there was a decrease in the MAP and heart frequency ($P<0.01$). GDFT resulted in an increase in SV ($P=0.003$), MAP ($P=0.003$), CVP ($P=0.01$), and CO ($P=0.003$) as well as a decrease in SVV ($P=0.01$) after first fluid optimization. SV remained elevated until the end of the intervention (Figure 2). In contrast, SVV was not lower at the end compared to after the first optimization (Figure 3). On average, in median, two (1;2.75) fluid boluses were necessary for optimization after induction, compared to one (1;2) after implantation of the aortic valve. More colloid and fewer crystalloid solutions were given in the intervention group than in the control group. Total volume replacement as well as total amount of blood products substituted were comparable as well as maximum dosage of norepinephrine intraoperatively and cumulative dosage of norepinephrine during intensive care (Table 3).

Duration of anesthesia was shorter in the intervention group, whereas duration of the interventional procedure was not different. There were no differences regarding ICU and hospital length of stay (LOS) and duration of invasive mechanical ventilation (Table 4). Thirty-one GDFT patients (77.5%) and 34 control patients (85%) suffered from at least one of the abovementioned complications. The number of complications per patient did not differ between groups (1.5 [1;3.5] vs. 2 [1;4], intervention group and control group, respectively). However, GDFT was associated with reduced rate of delirium (risk ratio 0.24; 95% confidence interval [CI] 0.08;0.7). See Table 5 for mortality and complications.

DISCUSSION

In this study, GDFT with colloids has been shown to be able to optimize SV amongst patients undergoing TAVR in general anesthesia. As per protocol, patients in the GDFT group received more colloid infusions and fewer crystalloid infusions than those in the control group. The total administered volume between both groups, however, did not differ. Time spent under anesthesia in the GDFT group was shorter. Though this study was not powered for, SV optimization and shorter anesthesia duration were associated with a lower incidence of post-interventional delirium. The optimization of perioperative DO₂ to the organs through administration of targeted volume boluses during cardiac and non-




Fig. 1 - Representation of the study protocol. HAES=hydroxyethylstarch; IBP=invasive blood pressure; ICU=intensive care unit; SOP=standard operating procedure; SV=stroke volume.

cardiac surgery has previously been described and successfully implemented into clinical routine^[9,16,17]. We thus aimed to examine the translation of this effective intraoperative strategy for the first time during TAVR. In our protocol, SV was optimized using colloid solution immediately following induction of anesthesia. On average, in median, the protocol-driven administration of two

(1;2.75) fluid boluses was sufficient to optimize SV, which may be interpreted as the absence of hemodynamic relevant fluid shift during TAVR. Interestingly, yet a significant decrease from baseline value after initial fluid challenge was detected for SV, SV did not remain lower at the end compared to after the first optimization in the course of the operation.

Table 1. Baseline characteristics of the study population.

	Control group (n=40)	Interventional group (n=40)	P-value
Age (years)	83 (80;85)	81.5 (73;86)	0.3
Sex (female/male)	22 (55%)/18 (45%)	18 (45%)/22 (55%)	0.5
Body height (cm)	165.5 (158;174)	168 (160;175)	0.5
Body weight (kg)	69.5 (58;78)	74.5 (66;88)	0.053
BMI (kg/m ²)	24.4 (23;27.5)	26.8 (23.6;30.3)	0.14
LVEF (%)	50 (43;60)	58 (45;60)	0.37
Access site			0.38
Transfemoral	31 (77.5%)	35 (87.5%)	
Transapical	9 (22.5%)	5 (12.5%)	
EuroSCORE I	17.8 (9.8;30)	15 (5.7;21.7)	0.3
EuroSCORE II	5.7 (3.7;11.6)	4.3 (2.7;8.3)	0.86

Parameters are shown as median and (25th percentile;75th percentile)

BMI=body mass index; EuroSCORE=European System for Cardiac Operative Risk Evaluation; LVEF=left ventricular ejection fraction

Table 2. Course of hemodynamic parameters during transcatheter aortic valve replacement in the interventional group.

	After induction	After 1 st optimization	After valve implantation	After 2 nd optimization	End of intervention
MAP	71 (60;83.2)	82 (72;91)	74 (65;81)	73 (65;81)	73 (66;80)
HF	66 (58;72)	63 (59;73)	71 (63;78)	68 (9.2)	68 (60;76)
CVP	9 (8;13.5)	15 (10;17)	15 (12;17)	15 (11;16)	13.5 (10;15)
CO	3.8 (3;4.7)	4.7 (3.8;5.6)	4.7 (4.1;5.9)	5 (4.1;5.9)	5 (3.9;5.6)
SV	60 (42;67)	70.5 (58;92.5)*	10.5 (5;18.2)	74 (64.2;87.5)	71.5 (61;8)
SVV	13 (7.7;22)	8 (4.2;13.7)*	10.5 (5;18.2)	9.5 (6;14)	10 (6;17.5)

Parameters are shown as median (25th percentile;75th percentile)

*Positive increase in SV

CO=cardiac output; CVP=central venous pressure; HF=heart frequency; MAP=mean arterial pressure; SV=stroke volume; SVV=stroke volume variation

The use of pulse contour analysis amongst patients with high-grade AS has not been thoroughly examined. Certain validation studies involving surgical aortic valve replacement have shown non-optimal agreement between measured CO values via pulse contour analysis and thermodilution analysis, with a recommendation to measure trends rather than the absolute values^[18-20]. Høiseith et al.^[21] examined 32 patients with high-grade AS and administered a 750 ml HAES bolus while measuring SV, SVV, and pulse pressure variation (PPV) via Flo Trac/Vigileo® monitoring during the preoperative period. The fluid challenge was repeated postoperatively on the ICU, and the same values were measured via esophageal Doppler. “Responders” were classified as showing a > 15% increase in SV after fluid challenge. A moderate predictive value for SVV and PPV preoperatively was shown (area under the receiver operating characteristic curve [AUC_{roc}] 0.77 and 0.75). However, after aortic valve replacement the positive predictive

value was improved (AUC_{roc} 0.90 and 0.95). The difference between the absolute value of the SV measured via esophageal Doppler (SV_{od}) and via FloTrac® (SV_{vig}) was high. Nevertheless, there was a good correlation between the change of SV_{od} and SV_{vig} before and after fluid challenge (trending ability). The authors thus concluded that the FloTrac® system can be used to monitor volume responsiveness amongst patients with high-grade AS^[22], which may be confirmed by our results. Petzoldt et al.^[20] showed that calibrated pulse contour analysis is valid and that in uncalibrated pulse contour measurements, the relative SV trend to be superior to single absolute values in 18 patients undergoing TAVR in severe AS. The dependency of the pulse contour analysis with the quality of the pulse curve is, however, an important limitation of the method. The high pressure gradient of the AS can alter the form of the pressure curve^[23] and could influence the measured value. Furthermore, the altered compliance of the left ventricle, as a




Fig. 2 - Responses of stroke volume (SV) to fluid boluses. The * indicates a positive increase in SV (central illustration).




Fig. 3 - Responses of stroke volume variation (SVV) to fluid boluses. The * indicates a decrease in SVV.

consequence of left-sided myocardial hypertrophy/stiffness, can lead to a diastolic dysfunction. This may decrease the ability of the left ventricle to adequately respond to an increase in preload with an associated rise in SV^[24].

In this study, GDFT commenced immediately after anesthesia induction and prior to the start of the TAVR intervention. Due to the standardized fasting period, certain patients may have been

hypovolemic before anesthesia induction. This may be further pronounced by the onset of anesthesia, which produces a relative hypovolemia^[25]. Various other studies have concluded that a preoperative substitution with a crystalloid infusion can augment hepatic perfusion, but not necessarily renal perfusion^[27]. Other groups have suggested that a preoperative crystalloid substitution offers no benefit for the patient^[28]. In these studies, CO was examined

Table 3. Intra-interventive volume replacement and catecholamine dosage.

	Control group (n=40)	Interventional group (n=40)	P-value
Colloids (ml)	500 (0;500)	750 (500;1000)	< 0.001
Crystalloids (ml)	500 (500;1000)	500 (0;500)	< 0.001
RBC (ml)	0 (0;300)	0 (0;150)	0.91
FFP (ml)	0 (0;0)	0 (0;0)	0.84
Total volume replacement (ml)	1000 (1000;1600)	1250 (1000;1500)	0.3
Maximum intraoperative norepinephrine dosage (µg/kg/min.)	0.05 (0.02;0.09)	0.05 (0.03;0.07)	0.67
Cumulative norepinephrine dosage on ICU (µg)	0.0 (0.0;0.0)	0.0 (0.0;0.15)	0.9

Parameters are shown as median (25th percentile;75th percentile)
FFP=fresh frozen plasma; ICU=intensive care unit; RBC=red blood cells

Table 4. Intra- and post-interventive patient characteristics.

	Control group (n=40)	Interventional group (n=40)	P-value
Length of anesthesia (min.)	148 (121;170)	120 (91;153)	0.003
Length of intervention (min.)	83 (70;93)	70 (60;94)	0.09
Length of hospital stay (days)	11 (7;14)	8 (7;16)	0.79
Length of ICU stay (days)	3 (2;6)	2 (1;6)	0.16
Need for post-procedural mechanical ventilation (n)	16	16	
Length of post-interventive mechanical ventilation (min.)	0 (0;55)	0 (0;255)	0.54

Parameters are shown as median (25th percentile;75th percentile)
ICU=intensive care unit

only in the observation by Raue et al.^[26]. They found that standard monitoring in awake patients offered no reliable information regarding the ideal timing or ideal amount of volume substitution needed. For this reason, the German Society of Anaesthesiology and Intensive Care Medicine, according to their S3 guidelines, has given the preoperative volume substitution an evidence rating of "Grade-B" ("can be given"), in order to replace an assumed volume deficit preoperatively, although no concrete evidence supports this recommendation. By individually optimizing SV, however, a targeted attempt has been shown to increase preload after induction of anesthesia in the here presented study.

As colloids were used in our protocol, it is obvious that only the intervention group received them in a larger amount. These results mirror that of other GDFT studies with similar protocols^[29-33]. RCTs could show that there is, however, a potential nephrotoxic effect of colloid solutions and that the administration of hydroxyethyl starch to critically ill patients can have negative consequences^[34-36]. The results of these RCTs led to restriction of use for colloid solutions in 2013, and ultimately to a suspension of approval from

the Pharmacovigilance Risk Assessment Committee (or PRAC) in 2018. According to the S3 guidelines from the German Society of Anesthesiology and Intensive Care Medicine, critically ill patients with recently occurring coagulation or renal disorders should not be administered colloid solutions^[37]. Our study took place before these restrictions and were in line with a consensus stating that colloid solutions can be used for hypovolemia and hemodynamic optimization amongst cardio-surgical patients^[37]. Though this study was not powered for, no evidence of renal or other complications associated with SV optimization using colloids were observed. ICU and hospital LOS between the examined groups did not differ as well. Peri- and post-procedural bleeding occurred relatively frequently in both groups (37.5% GDFT vs. 22.5% control). This could be due to the transfemoral insertion method, as it has been previously described that this method is associated with a higher risk for vascular complications and hemorrhage compared to the transapical method (8-28% vs. 3.6-7%)^[38]. Genereux et al.^[39] described the prevalence of bleeding and vascular complications to be 22.3% and 11.9%, respectively, and concluded that these

Table 5. Rate of complications.

	Control group	Interventional group	P-value
	(n=40)	(n=40)	
Total mortality	3 (7.5%)	3 (7.5%)	1
Delirium	17 (42.5%)	6 (15%)	0.006
Infectious complications	16 (40%)	22 (55%)	
Pneumoniae	9 (22.5%)	12 (30%)	0.61
Urinary tract infections	4 (10%)	2 (5%)	0.68
Others/unclear	4 (10%)	9 (22,5%)	0.13
Bleeding complications	9 (22.5%)	15 (37.5%)	0.22
Cardiovascular complications	16 (40%)	22 (55%)	
LBBB	9 (22.5%)	9 (22.5%)	1
Atrioventricular block (2 nd -3 rd degrees)	2 (5%)	8 (20%)	0.09
Absolute arrhythmia	5 (12.5%)	3 (7.5%)	0.71
Stroke	1 (2.5%)	1 (2.5%)	1
Others	0	1 (2.5%)	
Pulmonary complications	10 (25%)	13 (32.5%)	0.62
Acute kidney failure	8 (20%)	6 (15%)	0.77

Parameters are shown as absolute values and percentages
LBBB=left bundle branch block

complications have been underreported due to non-standardized definitions. They further noted an incidence of acute kidney injury (Acute Kidney Injury Network [AKIN] I-III) between 6.5% to 34.1% (pooled estimate rate 20.4%, 95% CI 16.2% to 25.8%), whereby the most cases (up to 26%) involve a light form of AKIN II [39]. In our study, a two-times increase of the preoperative creatinine was defined as renal failure, which equates to AKIN II. Therefore, according to our reporting, the total incidence of acute kidney injury was possibly underestimated by 20%.

In our study, 15% of the GDFT patients and 42.5% of the control patients developed postoperative delirium (POD). Information regarding the absolute incidence of POD for patients undergoing TAVR is still lacking in recent literature. Tse et al. [40] found that the prevalence of POD in conventional coronary artery bypass grafting, surgical valve replacement, and TAVR is 28% in a retrospective analysis of 679 cases of POD. In a subgroup analysis of 122 post TAVR patients, a POD incidence of 27% was found, and patients undergoing TAVR with the transapical method showed significantly higher rates of POD compared with the transfemoral method (12% vs. 53%) [41]. Concerning our study, transapical and transfemoral access were utilized in equal ratios in both GDFT and control groups, so the cause of POD solely due to the implantation route may be neglected.

As reported, the duration of anesthesia in the GDFT group was shorter than in the control group. As the GDFT group underwent TAVR at a later time period than the control group, this difference could be due to a "learning effect" [42]. This experience has also been documented in another study [43]. However, there is evidence

suggesting that exposition to deep [44] and long-period sedation [45] amongst intensive care patients is correlated with longer ventilation and hospital admission times, as well as increasing overall mortality. Additionally, other working groups have pointed out that deep sedation during ICU admission is a positive-predictive factor for the development of delirium [46,47]. The anti-cholinergic effect of many sedative agents has been described as a contributing factor of cerebral damage [48]. The exact cause is not clear at this time, and is most likely due to interactions with multiple central nervous system neuro-molecular pathways [48-50]. In conclusion, although our sample size was relatively small, there is evidence to suggest that GDFT and a shorter anesthesia time may be protective against the development of POD amongst patients undergoing TAVR. The exact cause of this remains unclear, however, GDFT can optimize cerebral perfusion and DO₂, thereby reducing the degree of cerebral damage, and the shorter anesthesia time leads to shorter exposition time under anesthetic agents [51]. As stated before, more studies examining the role GDFT plays in improving POD are needed, as the financial and social costs of POD are immense.

Limitations

This study has several limitations. First of all, this study was performed nearly 10 years ago. Nevertheless, it still demonstrates that SV can be optimized in TAVR patients. Secondly, in today's clinical practice, a huge number of TAVR is performed under monitored anesthesia care (MAC). There are ambiguous results regarding outcome difference between MAC and general anesthesia [52,53].

If additional GDFT in TAVR patients under MAC will be of any benefit, it must be evaluated in future studies. Third, this pilot study was a single-center analysis with a prospective intervention group and a retrospective control group. This ambispective study design by itself has intrinsic limitations. It cannot be ruled out that results are influenced by shorter duration of TAVR procedure and higher level of implantation skill of the team in the interventional group with increasing learning curve over time. Blinding for the intervention group was not planned or possible. The number of patients was not powered for any endpoint. Additionally, the follow-up was limited to hospital admission time. We did not register preinterventional cerebrovascular function, SV, as well as aortic valve function. Additionally, we did not monitor urine output during the intervention. GDFT and targeted SV optimization are promising strategies for the anesthesiologist to improve perioperative outcomes amongst patients undergoing mid to high-risk surgeries. However, GDFT is not thoroughly studied amongst minimally invasive, although high-risk, procedures, such as TAVR. Uncalibrated pulse contour analysis technique might have been not the best choice for patients undergoing interventional heart valve procedures as these are based on nomograms of a healthy cohort. We could show that GDFT was possible amongst the intervention group, and that an optimization of SV using colloid-based fluid challenges is feasible. Other outcomes, being that of POD and anesthesia time, are not highly powered enough to draw a broader conclusion. Moreover, a lesser rate of POD might have been caused by shorter anesthesia and intervention time. Additionally, factors like frailty, which certainly contributes significantly to the prevalence of periinterventional POD, were not examined systematically in our study. RCTs with these outcomes in mind, with a high patient cohort, and longer follow-up times are needed in order to truly gauge the effectiveness of this strategy for broader use.

CONCLUSION

In conclusion, to our knowledge, our study is the first attempt to apply GDFT to TAVR. Our protocol was feasible in optimizing SV. We noted a reduction in delirium but not in overall complications, overall mortality, and hospital and ICU LOS. Further studies are needed to show if this approach could achieve a better outcome for TAVR.

No financial support.

Conflict of interest: RFT, MN, GBF, HD, and KS have nothing to declare. MS received financial activities from Edwards Lifesciences, Medtronic, the Getinge Group, FERRER, AMOMED, Orion Pharma, Grünenthal, Fisher&Peykel, BTG, and Ratiopharm. ST received institutional research grant & honoraria for lectures/workshops by Orionpharma and Edwards and honoraria for lectures by Amomed outside this work. MH received payment from Edwards Lifesciences and AMOMED due to lecturing activities.

Authors' Roles & Responsibilities

RFT	Substantial contributions to the analysis and interpretation of data for the work; drafting the work; final approval of the version to be published
MN	Revising the work; final approval of the version to be published
GBF	Substantial contributions to the analysis and interpretation of data for the work; drafting the work; final approval of the version to be published
MS	Substantial contributions to the interpretation of data for the work; revising the work; final approval of the version to be published
HD	Revising the work; final approval of the version to be published
KS	Revising the work; final approval of the version to be published
ST	Substantial contributions to the interpretation of data for the work; drafting the work; final approval of the version to be published
MH	Substantial contributions to the analysis and interpretation of data for the work; revising the work; final approval of the version to be published

REFERENCES

1. Cribier A, Eltchaninoff H, Bash A, Borenstein N, Tron C, Bauer F, et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. *Circulation*. 2002;106(24):3006-8. doi:10.1161/01.cir.0000047200.36165.b8.
2. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. *N Engl J Med*. 2010;363(17):1597-607. doi:10.1056/NEJMoa1008232.
3. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. *N Engl J Med*. 2011;364(23):2187-98. doi:10.1056/NEJMoa1103510.
4. Van Mieghem NM, Deeb GM, Søndergaard L, Grube E, Windecker S, Gada H, et al. Self-expanding transcatheter vs surgical aortic valve replacement in intermediate-risk patients: 5-year outcomes of the SURTAVI randomized clinical trial. *JAMA Cardiol*. 2022;7(10):1000-8. doi:10.1001/jamacardio.2022.2695.
5. Cecconi M, Corredor C, Arulkumaran N, Abuella G, Ball J, Grounds RM, et al. Clinical review: Goal-directed therapy-what is the evidence in surgical patients? The effect on different risk groups. *Crit Care*. 2013;17(2):209. doi:10.1186/cc11823.
6. Dalfino L, Giglio MT, Puntillo F, Marucci M, Brienza N. Haemodynamic goal-directed therapy and postoperative infections: earlier is better. A systematic review and meta-analysis. *Crit Care*. 2011;15(3):R154. doi:10.1186/cc10284.
7. Deng QW, Tan WC, Zhao BC, Wen SH, Shen JT, Xu M. Is goal-directed fluid therapy based on dynamic variables alone sufficient to improve clinical outcomes among patients undergoing surgery? A meta-analysis. *Crit Care*. 2018;22(1):298. doi:10.1186/s13054-018-2251-2.
8. Hamilton MA, Cecconi M, Rhodes A. A systematic review and meta-analysis on the use of preemptive hemodynamic intervention to improve postoperative outcomes in moderate and high-risk surgical patients. *Anesth Analg*. 2011;112(6):1392-402. doi:10.1213/ANE.0b013e3181eeaae5.
9. Habicher M, Balzer F, Mezger V, Niclas J, Müller M, Perka C, et al. Implementation of goal-directed fluid therapy during hip revision arthroplasty: a matched cohort study. *Perioper Med (Lond)*. 2016;5:31. doi:10.1186/s13741-016-0056-x.

10. Aya HD, Cecconi M, Hamilton M, Rhodes A. Goal-directed therapy in cardiac surgery: a systematic review and meta-analysis. *Br J Anaesth*. 2013;110(4):510-7. doi:10.1093/bja/aet020.
11. Bartha E, Arfwedson C, Imnell A, Fernlund ME, Andersson LE, Kalman S. Randomized controlled trial of goal-directed haemodynamic treatment in patients with proximal femoral fracture. *Br J Anaesth*. 2013;110(4):545-53. doi:10.1093/bja/aes468.
12. Funk DJ, HayGlass KT, Koulack J, Harding G, Boyd A, Brinkman R. A randomized controlled trial on the effects of goal-directed therapy on the inflammatory response open abdominal aortic aneurysm repair. *Crit Care*. 2015;19(1):247. doi:10.1186/s13054-015-0974-x.
13. Feldheiser A, Pavlova V, Weimann K, Hunsicker O, Stockmann M, Koch M, et al. Haemodynamic optimization by oesophageal doppler and pulse power wave analysis in liver surgery: a randomised controlled trial. *PLoS One*. 2015;10(7):e0132715. doi:10.1371/journal.pone.0132715.
14. Li P, Qu LP, Qi D, Shen B, Wang YM, Xu JR, et al. Significance of perioperative goal-directed hemodynamic approach in preventing postoperative complications in patients after cardiac surgery: a meta-analysis and systematic review. *Ann Med*. 2017;49(4):343-51. doi:10.1080/07853890.2016.1271956.
15. Senagore AJ, Emery T, Luchtfeld M, Kim D, Dujovny N, Hoedema R. Fluid management for laparoscopic colectomy: a prospective, randomized assessment of goal-directed administration of balanced salt solution or hetastarch coupled with an enhanced recovery program. *Dis Colon Rectum*. 2009;52(12):1935-40. doi:10.1007/DCR.0b013e3181b4c35e.
16. Pearse R, Dawson D, Fawcett J, Rhodes A, Grounds RM, Bennett ED. Early goal-directed therapy after major surgery reduces complications and duration of hospital stay. A randomised, controlled trial [ISRCTN38797445]. *Crit Care*. 2005;9(6):R687-93. doi:10.1186/cc3887.
17. Mythen MG, Webb AR. Perioperative plasma volume expansion reduces the incidence of gut mucosal hypoperfusion during cardiac surgery. *Arch Surg*. 1995;130(4):423-9. doi:10.1001/archsurg.1995.01430040085019.
18. Lorsomradee S, Lorsomradee S, Cromheecke S, De Hert SG. Uncalibrated arterial pulse contour analysis versus continuous thermodilution technique: effects of alterations in arterial waveform. *J Cardiothorac Vasc Anesth*. 2007;21(5):636-43. doi:10.1053/j.jvca.2007.02.003.
19. Staier K, Wiesenack C, Günkel L, Keyl C. Cardiac output determination by thermodilution and arterial pulse waveform analysis in patients undergoing aortic valve replacement. *Can J Anaesth*. 2008;55(1):22-8. doi:10.1007/BF03017593.
20. Petzoldt M, Riedel C, Braeunig J, Haas S, Goepfert MS, Treede H, et al. Stroke volume determination using transcardiopulmonary thermodilution and arterial pulse contour analysis in severe aortic valve disease. *Intensive Care Med*. 2013;39(4):601-11. doi:10.1007/s00134-012-2786-7.
21. Høiseeth LØ, Hoff IE, Hagen OA, Landsverk SA, Kirkebøen KA. Dynamic variables and fluid responsiveness in patients for aortic stenosis surgery. *Acta Anaesthesiol Scand*. 2014;58(7):826-34. doi:10.1111/aas.12328.
22. Høiseeth LØ, Hoff IE, Hagen OA, Landsverk SA, Kirkebøen KA. Agreement between stroke volume measured by oesophageal doppler and uncalibrated pulse contour analysis during fluid loads in severe aortic stenosis. *J Clin Monit Comput*. 2015;29(4):435-41. doi:10.1007/s10877-015-9666-y.
23. Stergiopoulos N, Young DF, Rogge TR. Computer simulation of arterial flow with applications to arterial and aortic stenoses. *J Biomech*. 1992;25(12):1477-88. doi:10.1016/0021-9290(92)90060-e.
24. Hess OM, Villari B, Krayenbuehl HP. Diastolic dysfunction in aortic stenosis. *Circulation*. 1993;87(5 Suppl):IV73-6.
25. Bundgaard-Nielsen M, Jørgensen CC, Secher NH, Kehlet H. Functional intravascular volume deficit in patients before surgery. *Acta Anaesthesiol Scand*. 2010;54(4):464-9. doi:10.1111/j.1399-6576.2009.02175.x.
26. Raue W, Haase O, Langelotz C, Neuss H, Müller JM, Schwenk W. Influence of pre-operative fluid infusion on volume status during oesophageal resection—a prospective trial. *Acta Anaesthesiol Scand*. 2008;52(9):1218-25. doi:10.1111/j.1399-6576.2008.01759.x.
27. Serrano AB, Candela-Toha AM, Zamora J, Vera J, Muriel A, Del Rey JM, et al. Preoperative hydration with 0.9% normal saline to prevent acute kidney injury after major elective open abdominal surgery: a randomised controlled trial. *Eur J Anaesthesiol*. 2016;33(6):436-43. doi:10.1097/EJA.0000000000000421.
28. Brandstrup B. Fluid therapy for the surgical patient. *Best Pract Res Clin Anaesthesiol*. 2006;20(2):265-83. doi:10.1016/j.bpa.2005.10.007.
29. Benes J, Chytra I, Altmann P, Hluchy M, Kasal E, Svitak R, et al. Intraoperative fluid optimization using stroke volume variation in high risk surgical patients: results of prospective randomized study. *Crit Care*. 2010;14(3):R118. doi:10.1186/cc9070.
30. Gan TJ, Soppitt A, Maroof M, el-Moalem H, Robertson KM, Moretti E, et al. Goal-directed intraoperative fluid administration reduces length of hospital stay after major surgery. *Anesthesiology*. 2002;97(4):820-6. doi:10.1097/00000542-200210000-00012.
31. Lopes MR, Oliveira MA, Pereira VO, Lemos IP, Auler JO Jr, Michard F. Goal-directed fluid management based on pulse pressure variation monitoring during high-risk surgery: a pilot randomized controlled trial. *Crit Care*. 2007;11(5):R100. doi:10.1186/cc6117.
32. Mayer J, Boldt J, Mengistu AM, Röhm KD, Suttner S. Goal-directed intraoperative therapy based on autocalibrated arterial pressure waveform analysis reduces hospital stay in high-risk surgical patients: a randomized, controlled trial. *Crit Care*. 2010;14(1):R18. doi:10.1186/cc8875.
33. Mythen MG, Webb AR. Intra-operative gut mucosal hypoperfusion is associated with increased post-operative complications and cost. *Intensive Care Med*. 1994;20(2):99-104. doi:10.1007/BF01707662.
34. Myburgh JA, Finfer S, Bellomo R, Billot L, Cass A, Gattas D, et al. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. *N Engl J Med*. 2012;367(20):1901-11. Erratum in: *N Engl J Med*. 2016;374(13):1298. doi:10.1056/NEJMoa1209759.
35. Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Åneman A, et al. Hydroxyethyl starch 130/0.42 versus ringer's acetate in severe sepsis. *N Engl J Med*. 2012;367(2):124-34. Erratum in: *N Engl J Med*. 2012;367(5):481. doi:10.1056/NEJMoa1204242.
36. Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. *N Engl J Med*. 2008;358(2):125-39. doi:10.1056/NEJMoa070716.
37. Habicher M, Zajonz T, Heringlake M, Böning A, Treskatsch S, Schirmer U, et al. S3- [S3 guidelines on intensive medical care of cardiac surgery patients : hemodynamic monitoring and cardiovascular system-an update]. *Anaesthesist*. 2018;67(5):375-9. German. doi:10.1007/s00101-018-0433-6.
38. Guinot PG, Depoix JP, Etchegoyen L, Benbara A, Provenchère S, Dilly MP, et al. Anesthesia and perioperative management of patients undergoing transcatheter aortic valve implantation: analysis of 90 consecutive patients with focus on perioperative complications. *J Cardiothorac Vasc Anesth*. 2010;24(5):752-61. doi:10.1053/j.jvca.2009.12.019.
39. Généreux P, Head SJ, Van Mieghem NM, Kodali S, Kirtane AJ, Xu K, et al. Clinical outcomes after transcatheter aortic valve replacement using valve academic research consortium definitions: a weighted meta-analysis of 3,519 patients from 16 studies. *J Am Coll Cardiol*. 2012;59(25):2317-26. doi:10.1016/j.jacc.2012.02.022.
40. Tse L, Schwarz SK, Bowering JB, Moore RL, Barr AM. Incidence of and risk factors for delirium after cardiac surgery at a quaternary care center: a retrospective cohort study. *J Cardiothorac Vasc Anesth*. 2015;29(6):1472-9. doi:10.1053/j.jvca.2015.06.018.
41. Tse L, Bowering JB, Schwarz SK, Moore RL, Burns KD, Barr AM. Postoperative delirium following transcatheter aortic valve implantation: a historical cohort study. *Can J Anaesth*. 2015;62(1):22-30. doi:10.1007/s12630-014-0254-2.

42. Webb JG, Pasupati S, Humphries K, Thompson C, Altwegg L, Moss R, et al. Percutaneous transarterial aortic valve replacement in selected high-risk patients with aortic stenosis. *Circulation*. 2007;116(7):755-63. doi:10.1161/CIRCULATIONAHA.107.698258.
43. Grube E, Buellesfeld L, Mueller R, Sauren B, Zickmann B, Nair D, et al. Progress and current status of percutaneous aortic valve replacement: results of three device generations of the CoreValve Revalving system. *Circ Cardiovasc Interv*. 2008;1(3):167-75. doi:10.1161/CIRCINTERVENTIONS.108.819839.
44. Shehabi Y, Bellomo R, Reade MC, Bailey M, Bass F, Howe B, et al. Early intensive care sedation predicts long-term mortality in ventilated critically ill patients. *Am J Respir Crit Care Med*. 2012;186(8):724-31. doi:10.1164/rccm.201203-0522OC.
45. Girard TD, Kress JP, Fuchs BD, Thomason JW, Schweickert WD, Pun BT, et al. Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (awakening and breathing controlled trial): a randomised controlled trial. *Lancet*. 2008;371(9607):126-34. doi:10.1016/S0140-6736(08)60105-1.
46. van den Boogaard M, Pickkers P, Slooter AJ, Kuiper MA, Spronk PE, van der Voort PH, et al. Development and validation of PRE-DELIRIC (PREdiction of DELIRium in ICU patients) delirium prediction model for intensive care patients: observational multicentre study. *BMJ*. 2012;344:e420. doi:10.1136/bmj.e420.
47. Ouimet S, Kavanagh BP, Gottfried SB, Skrobik Y. Incidence, risk factors and consequences of ICU delirium. *Intensive Care Med*. 2007;33(1):66-73. doi:10.1007/s00134-006-0399-8.
48. Hollinger A, Siegemund M, Goettel N, Steiner LA. Postoperative delirium in cardiac surgery: an unavoidable menace? *J Cardiothorac Vasc Anesth*. 2015;29(6):1677-87. doi:10.1053/j.jvca.2014.08.021.
49. Burkhart CS, Dell-Kuster S, Gamberini M, Moeckli A, Grapow M, Filipovic M, et al. Modifiable and nonmodifiable risk factors for postoperative delirium after cardiac surgery with cardiopulmonary bypass. *J Cardiothorac Vasc Anesth*. 2010;24(4):555-9. doi:10.1053/j.jvca.2010.01.003.
50. Lin Y, Chen J, Wang Z. Meta-analysis of factors which influence delirium following cardiac surgery. *J Card Surg*. 2012;27(4):481-92. doi:10.1111/j.1540-8191.2012.01472.x.
51. Hori D, Max L, Laflam A, Brown C, Neufeld KJ, Adachi H, et al. Blood pressure deviations from optimal mean arterial pressure during cardiac surgery measured with a novel monitor of cerebral blood flow and risk for perioperative delirium: a pilot study. *J Cardiothorac Vasc Anesth*. 2016;30(3):606-12. doi:10.1053/j.jvca.2016.01.012.
52. Thiele H, Kurz T, Feistritz HJ, Stachel G, Hartung P, Lurz P, et al. General versus local anesthesia with conscious sedation in transcatheter aortic valve implantation: the randomized SOLVE-TAVI trial. *Circulation*. 2020;142(15):1437-47. doi:10.1161/CIRCULATIONAHA.120.046451.
53. Téllez-Alarcón M, Montes FR, Hurtado P, Gutiérrez LP, Cabrales JR, Camacho J, et al. Conscious sedation versus general anesthesia for transcatheter aortic valve implantation: a retrospective study. *Braz J Anesthesiol*. 2022;72(4):539-541. doi:10.1016/j.bjane.2021.11.009.

